NIH Summary Statement: How to Read & Respond

An NIH study section does not just score an application — it produces a written record of that review, called a summary statement. Long-time NIH applicants still routinely call it the “pink sheet,” a name that dates back to when reviewers’ critiques were physically mailed to applicants on pink-colored paper; the nickname stuck even after NIH moved distribution entirely into eRA Commons. This guide covers how to actually read the document — the scores, the percentile, the individual critiques — and how to decide and act on what comes next. It does not cover how study sections are convened or how applications get assigned to one, which CASRAI’s NIH Study Section entry covers separately, and it does not cover the full NIH-vs-NSF resubmission comparison, which lives on CASRAI’s NIH vs. NSF Resubmission Policy page.

What a Summary Statement Contains

A summary statement is released to the applicant (via the Signing Official and Program Director/Principal Investigator accounts in eRA Commons) after the study section meeting concludes and before the funding Institute or Center’s advisory council performs its second-level programmatic review. A typical summary statement includes:

Resume and summary of discussion — a short paragraph, written collectively by the Scientific Review Officer based on the panel’s discussion, summarizing the study section’s overall view of the application’s strengths and weaknesses. For applications that were not discussed at the meeting (see below), this section is typically much shorter, since only the assigned reviewers’ written critiques exist.
Individual reviewer critiques — each assigned reviewer’s written comments, organized by review criterion, submitted before the meeting and not substantively changed by the panel discussion (a reviewer’s pre-meeting score can move after discussion; their written critique generally does not get rewritten to match).
Criterion scores — each assigned reviewer’s individual 1–9 score for every core review criterion (see below).
Overall impact score — for discussed applications, the panel’s post-discussion 1–9 scores from all eligible voting members, averaged and multiplied by 10 to produce the priority score (e.g., an average of 2.3 becomes a priority score of 23).
Percentile rank — where the priority score falls relative to other applications reviewed by that same study section (see below). Not every application receives one — some mechanisms and some ICs use priority score alone.
Administrative notes and budget recommendations — any recommended changes to the requested budget or project period, and notes on human subjects, vertebrate animals, biohazard, or select agent concerns the panel flagged, which the assigned Institute or Center will expect to see addressed before an award, if the application is funded.

Criterion Scores and the Overall Impact Score

NIH peer reviewers score research grant applications against a set of core review criteria — commonly Significance, Investigator(s), Innovation, Approach, and Environment for most research project grants (the exact criteria set varies somewhat by activity code and funding opportunity). Each criterion gets its own 1–9 score from each assigned reviewer, where 1 is exceptional and 9 is poor. A critical point applicants often misunderstand: there is no formula that derives the overall impact score from the criterion scores. A reviewer can score Approach a 3 and Significance a 2 and still give an overall impact score of 4, because the overall score is meant to capture the reviewer’s holistic judgment of the project’s likely impact, not a mechanical average of the individual criteria. Weak individual criterion scores are diagnostic of where the reviewer saw a problem; they are not, on their own, the number that determines fundability — the overall impact score and resulting priority score are.

Only applications the study section chooses to discuss at the meeting receive a final overall impact score and priority score from the full panel. Applications in roughly the bottom half of a study section’s preliminary (pre-meeting) scores are typically not discussed (sometimes called being “streamlined”) — these still receive a summary statement with the individual reviewers’ written critiques and preliminary criterion scores, but no panel-discussed overall score or percentile.

Understanding Your Percentile Rank

The percentile rank is not a score in its own right — it is a ranking of your application’s priority score against the distribution of priority scores from the same study section’s meetings over roughly the preceding year (its recent review cycles), not against every NIH application nationally. A lower percentile is better: it means your priority score outperformed a larger share of that comparison set. This is also why the same priority score can carry a different percentile from one study section to another, or from one round to the next for the same study section — the comparison pool shifts each cycle.

The percentile is what gets compared against an Institute or Center’s payline for a given fiscal year to gauge funding likelihood, though a payline is a planning guideline, not a guarantee or a hard cutoff — ICs retain discretion to fund out of percentile order for programmatic reasons. CASRAI’s guide to NIH R01 success rates and paylines by institute covers how to find and interpret a given IC’s current payline.

How to Read the Critiques

The written critiques are where the actual, actionable information lives — the scores tell you roughly where you stand, but the critiques tell you why, and that is what a resubmission has to respond to. A few practical habits help:

Separate a pattern from a single reviewer’s idiosyncratic opinion. If two or three reviewers independently raise the same concern (e.g., an underpowered analysis plan, an unclear primary outcome), treat it as a real weakness the panel likely weighted. A single reviewer’s one-off comment that the others don’t echo carries less weight, though it may still be worth a brief response if it is easy to address.
Distinguish a fixable methodological gap from a fundamental critique of the premise. Comments about missing preliminary data, an underspecified statistical plan, or an unclear timeline are usually addressable by revision. Comments questioning whether the central hypothesis is significant or novel enough are harder to fix without substantially reframing the project — and are the strongest signal that resubmission may not be the right path.
Read the resume/summary of discussion alongside the individual critiques, not instead of it. The summary reflects what the panel discussed collectively (for discussed applications); the individual critiques may raise points that were not extensively debated in the room but still matter to the reviewer who wrote them.
Treat administrative and regulatory notes as non-optional. Concerns flagged about human subjects protections, vertebrate animal welfare, or biosafety are not scored the same way as scientific critique, but an Institute or Center will generally require them to be resolved before an award is made, independent of the resubmission decision.

Deciding Whether to Resubmit (A1) or Submit as New (A0)

Under NIH policy, an unfunded original application (A0) may be revised and resubmitted exactly once, as an A1, within 37 months of the original application’s receipt date; if the A1 is also not funded, there is no A2 — the only path forward is a new A0 application. CASRAI’s NIH vs. NSF Resubmission Policy comparison covers this rule, the 37-month window, and how it differs from NSF’s approach in full detail. Given that a resubmission is a one-time option, deciding whether to use it is worth treating deliberately:

Resubmission tends to make sense when the percentile or priority score was reasonably close to the payline, the critiques point to specific, addressable weaknesses (a study design gap, missing preliminary data, an underdeveloped analysis plan), and the core premise and significance were not seriously challenged.
Starting over as a new A0 (on the same idea, substantially reworked, or a different idea) tends to make more sense when the critiques challenge the project’s fundamental significance or innovation, when addressing every major point would require a project that is essentially different from the one reviewed, or when the score was far from the payline with no clear, bounded fix.
A resubmission cannot be filed before the summary statement from the prior review is issued, since the required Introduction has to respond to it directly — factor that timing into a lab’s planning, especially against the 37-month window.

How to Structure a Resubmission

Every NIH resubmission application must include an Introduction to Application attachment — capped at one page for most research grant applications (check the specific funding opportunity announcement, since page limits vary by activity code) — that summarizes the substantial additions, deletions, and changes made since the prior submission and responds directly to the concerns raised in the summary statement. A few conventions matter in practice:

Address the critique point by point, not defensively. NIH guidance and experienced reviewers consistently advise against a rebuttal-style tone that argues the prior reviewers were wrong. Even where an applicant genuinely disagrees with a critique, the more effective approach is to explain what was changed (additional data, a revised design, clarified language) and why, rather than contesting the original assessment.
Make the changes visible in the resubmission itself, not just in the Introduction. Reviewers commonly recommend marking substantial changes in the body of the resubmitted application (e.g., with a change bar or bracketed text, consistent with the funding opportunity’s instructions) so a new or returning reviewer can see exactly what moved without re-reading the entire application line by line.
Prioritize the concerns that most affected the score. With only one page, an Introduction cannot exhaustively re-litigate every critique line; it needs to demonstrate that the major weaknesses were addressed, with any minor points handled briefly or folded into the revised text itself.
Assume at least some reviewer continuity, but do not depend on it. A resubmission is not guaranteed to go back to the same study section or the same individual reviewers. Write the Introduction so it stands on its own for a reviewer encountering the project for the first time, while still directly answering the specific points raised in the prior summary statement.

Common Mistakes When Responding to a Summary Statement

Reacting to the overall impact score alone and skipping the critiques. The score tells you roughly where the application landed; the critiques tell you what to actually change. A resubmission built only around “the score needs to be lower” without engaging the written concerns rarely succeeds.
Treating every reviewer comment as equally weighted. Comments echoed by multiple reviewers, or that clearly drove the overall score, need to be addressed substantively; isolated, minor comments can usually be handled briefly.
Writing the Introduction in a defensive or argumentative register. This is one of the more consistent pieces of advice from experienced NIH applicants and program staff, and it lines up with NIH’s own framing of the Introduction as a summary of changes, not a rebuttal.
Missing the 37-month resubmission window by treating the A1 deadline as flexible, or waiting too long after the summary statement to start revising.
Ignoring administrative or regulatory notes (human subjects, vertebrate animals, biosafety) because they were not part of the scientific critique — these still need resolution before an award, resubmission or not.

Frequently Asked Questions

What does a percentile score on an NIH summary statement actually mean?

It ranks your application’s priority score against the distribution of priority scores from the same study section’s recent meetings (roughly the past year), not against all NIH applications nationally. A lower percentile is better.

Why didn’t my application get a percentile or an overall impact score?

Only applications the study section chooses to discuss at the meeting receive a panel-voted overall impact score and, typically, a percentile. Applications scoring in roughly the lower half at the pre-meeting stage are usually not discussed; they still receive a summary statement with the individual reviewers’ written critiques and preliminary criterion scores.

Should I resubmit or submit a new application?

It depends on what the critiques actually say. If the concerns are specific and addressable (a study design gap, missing preliminary data) and the score was reasonably close to the payline, a resubmission (A1) is usually the better use of the one resubmission NIH allows. If reviewers questioned the project’s fundamental significance or innovation, restarting as a new A0 — possibly with a substantially reworked idea — is often more productive than spending the one resubmission opportunity trying to overcome that kind of critique.

How long do I have to submit an NIH resubmission?

An A1 resubmission must be submitted within 37 months of the original (A0) application’s receipt date. After that window, NIH will not accept it as a resubmission — it has to go in as a new A0 application instead.

Can I resubmit a second time if my A1 is also not funded?

No. NIH accepts only one resubmission (A1) per original application. If the A1 is not funded, the only path forward is to submit the idea as a new A0 application, which is reviewed independently and starts the process over.

References

NINDS, “Scoring and Summary Statements” — what a summary statement contains and how criterion, overall impact, and percentile scores relate.
NIH Office of Extramural Research (Nexus), “Understanding Your Peer Review Summary Statement”.
NIH Center for Scientific Review, “Study Sections” — the review process that produces the summary statement; see also CASRAI’s NIH Study Section entry.
NIH Grants Policy Statement, section 2.4, “The Peer Review Process” — the two-level review structure and the role of the summary statement between study section and advisory council review.
CASRAI, NIH vs. NSF Resubmission Policy — full detail on the A0/A1 designation, the 37-month window, and the Introduction attachment requirement.